Correlation Between Arrowhead Pharmaceuticals and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Arrowhead Pharmaceuticals and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arrowhead Pharmaceuticals and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arrowhead Pharmaceuticals and Molecular Partners AG, you can compare the effects of market volatilities on Arrowhead Pharmaceuticals and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arrowhead Pharmaceuticals with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arrowhead Pharmaceuticals and Molecular Partners.

Diversification Opportunities for Arrowhead Pharmaceuticals and Molecular Partners

0.34

Correlation Coefficient

Arrowhead Pharmaceuticals  Molecular Partners

Weak diversification

The 3 months correlation between Arrowhead and Molecular is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Arrowhead Pharmaceuticals and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Arrowhead Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arrowhead Pharmaceuticals are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Arrowhead Pharmaceuticals i.e., Arrowhead Pharmaceuticals and Molecular Partners go up and down completely randomly.

Pair Corralation between Arrowhead Pharmaceuticals and Molecular Partners

Given the investment horizon of 90 days Arrowhead Pharmaceuticals is expected to under-perform the Molecular Partners. In addition to that, Arrowhead Pharmaceuticals is 1.4 times more volatile than Molecular Partners AG. It trades about -0.32 of its total potential returns per unit of risk. Molecular Partners AG is currently generating about -0.22 per unit of volatility. If you would invest  551.00  in Molecular Partners AG on October 4, 2024 and sell it today you would lose (76.20) from holding Molecular Partners AG or give up 13.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	95.45%
Values	Daily Returns

Arrowhead Pharmaceuticals  vs.  Molecular Partners AG

Arrowhead Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Arrowhead Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Arrowhead Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Molecular Partners

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Molecular Partners may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Arrowhead Pharmaceuticals and Molecular Partners

The main advantage of trading using opposite Arrowhead Pharmaceuticals and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arrowhead Pharmaceuticals position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Arrowhead Pharmaceuticals and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.